NA Electronic Clinical Outcome Assessment (eCOA) Market - Industry Trends and Forecast to 2030

TABLE OF CONTENT

1 INTRODUCTION 11
1.1 OBJECTIVES OF THE STUDY 11
1.2 MARKET DEFINITION 11
1.3 OVERVIEW OF THE NORTH AMERICA ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) MARKET 12
1.4 LIMITATIONS 13
1.5 MARKETS COVERED 13
2 MARKET SEGMENTATION 15
2.1 MARKETS COVERED 15
2.2 GEOGRAPHICAL SCOPE 16
2.3 YEARS CONSIDERED FOR THE STUDY 17
2.4 CURRENCY AND PRICING 17
2.5 Cognate Lifesciences TRIPOD DATA VALIDATION MODEL 18
2.6 MULTIVARIATE MODELLING 21
2.7 PRODUCTS LIFELINE CURVE 21
2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 22
2.9 Cognate Lifesciences MARKET POSITION GRID 23
2.10 MARKET END USER COVERAGE GRID 24
2.11 VENDOR SHARE ANALYSIS 25
2.12 SECONDARY SOURCES 26
2.13 ASSUMPTIONS 26
3 EXECUTIVE SUMMARY 27
4 PREMIUM INSIGHTS 30
4.1 PESTEL ANALYSIS 31
4.2 PORTER’S FIVE FORCES 32
5 REGULATORY FRAMEWORK 33
5.1 ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) 33
5.2 REGULATORY FRAMEWORK FOR ECOA 33
5.3 ICH E6 (R2) 33
5.4 FDA GUIDANCE 33
5.5 EMA GUIDELINES 33
5.5.1 ISO 14155 34
5.5.2 PRIVACY REGULATIONS 34 
6 MARKET OVERVIEW 35
6.1 DRIVERS 37
6.1.1 GROWING ACCEPTANCE OF ECOA AMONG CLINICAL RESEARCH PROFESSIONALS 37
6.1.2 PARADIGM SHIFT TOWARDS ELECTRONIC DATA CAPTURING FROM PAPER-BASED PROCEDURES 38
6.1.3 GOVERNMENT INITIATIVES ABOUT THE ADOPTION OF ECLINICAL PLATFORMS 39
6.2 RESTRAINTS 39
6.2.1 IMPLEMENTATION OF ‘BRING YOUR OWN DEVICE’ (BYOD) TECHNOLOGY IN CLINICAL TRIALS 39
6.2.2 LACK OF PROPER HEALTHCARE IT INFRASTRUCTURE IN DEVELOPING COUNTRIES 40
6.3 OPPORTUNITIES 42
6.3.1 GROWING ADOPTION OF CLOUD BASED SERVICES 42
6.3.2 RISING NUMBER OF RESEARCH STUDIES FOCUSING ON CLINICAL OUTCOME ASSESSMENTS 42
6.4 CHALLENGES 43
6.4.1 DIFFICULTIES ASSOCIATED WITH TRAINING OF RESPONDENTS TO FILL ELECTRONIC QUESTIONNAIRES 43
6.4.2 STREAMLINING OF ECOA SERVICES 43
7 NORTH AMERICA ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) MARKET, BY TYPE 45
7.1 OVERVIEW 46
7.2 CLINICIAN REPORTED OUTCOME ASSESSMENT (CLINRO) 49
7.3 PATIENT REPORTED OUTCOME ASSESSMENT (PRO) 49
7.4 OBSERVER REPORTED OUTCOME ASSESSMENT (OBSRO) 49
7.5 PERFORMANCE OUTCOME ASSESSMENT (PERFO) 49
8 NORTH AMERICA ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) MARKET, BY MODALITY 50
8.1 OVERVIEW 51
8.2 SITE-BASED SOLUTIONS 54
8.3 WEB SOLUTIONS 54
8.4 HANDHELD 54
8.4.1 BRING-YOUR-OWN-DEVICE (BYOD) 54
8.4.2 PROVISIONED DEVICES 54 
9 NORTH AMERICA ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) MARKET, BY END USER 55
9.1 OVERVIEW 56
9.2 CONTRACT RESEARCH ORGANIZATIONS (CROS) 59
9.3 PHARMACEUTICAL AND BIOTECHNOLOGY FIRMS 59
9.4 MEDICAL DEVICE COMPANIES 59
9.5 HOSPITALS/HEALTHCARE PROVIDERS 59
9.6 CONSULTING SERVICE COMPANIES 59
9.7 ACADEMIC & RESEARCH INSTITUTES 59
9.8 OTHERS 59
10 NORTH AMERICA ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) MARKET, BY DELIVERY MODE 60
10.1 OVERVIEW 61
10.2 CLOUD-BASED 64
10.3 WEB-HOSTED 64
11 NORTH AMERICA ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) MARKET BY GEOGRAPHY 65
11.1 NORTH AMERICA 65
11.1.1 U.S. 65
11.1.2 CANADA 65
11.1.3 MEXICO 65
12 NORTH AMERICA ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) MARKET, COMPANY LANDSCAPE 66
12.1 COMPANY SHARE ANALYSIS: NORTH AMERICA 66
13 SWOT ANALYSIS 67
14 COMPANY PROFILE 68
14.1 MEDIDATA 68
14.1.1 COMPANY SNAPSHOT 68
14.1.2 REVENUE ANALYSIS 68
14.1.3 COMPANY SHARE ANALYSIS 69
14.1.4 PRODUCT PORTFOLIO 69
14.1.5 RECENT DEVELOPMENTS 69 
14.2 CLARIO 70
14.2.1 COMPANY SNAPSHOT 70
14.2.2 COMPANY SHARE ANALYSIS 70
14.2.3 PRODUCT PORTFOLIO 71
14.2.4 RECENT DEVELOPMENT 71
14.3 IBM 72
14.3.1 COMPANY SNAPSHOT 72
14.3.2 REVENUE ANALYSIS 72
14.3.3 COMPANY SHARE ANALYSIS 73
14.3.4 PRODUCT PORTFOLIO 73
14.3.5 RECENT DEVELOPMENT 73
14.4 SIGNANT HEALTH 74
14.4.1 COMPANY SNAPSHOT 74
14.4.2 COMPANY SHARE ANALYSIS 74
14.4.3 PRODUCT PORTFOLIO 75
14.4.4 RECENT DEVELOPMENTS 75
14.5 IQVIA INC, 76
14.5.1 COMPANY SNAPSHOT 76
14.5.2 REVENUE ANALYSIS 76
14.5.3 COMPANY SHARE ANALYSIS 77
14.5.4 PRODUCT PORTFOLIO 77
14.5.5 RECENT DEVELOPMENT 77
14.6 ARISNORTH AMERICA 78
14.6.1 COMPANY SNAPSHOT 78
14.6.2 PRODUCT PORTFOLIO 78
14.6.3 RECENT DEVELOPMENTS 79
14.7 CASTOR 80
14.7.1 COMPANY SNAPSHOT 80
14.7.2 PRODUCT PORTFOLIO 80
14.7.3 RECENT DEVELOPMENTS 80
14.8 CLOUDBYZ 81
14.8.1 COMPANY SNAPSHOT 81
14.8.2 PRODUCT PORTFOLIO 81
14.8.3 RECENT DEVELOPMENT 81
14.9 CLINICAL INK. 82
14.9.1 COMPANY SNAPSHOT 82
14.9.2 PRODUCT PORTFOLIO 82
14.9.3 RECENT DEVELOPMENT 82 
14.10 EVIDENTIQ 83
14.10.1 COMPANY SNAPSHOT 83
14.10.2 PRODUCT PORTFOLIO 83
14.10.3 RECENT DEVELOPMENT 83
14.11 FOUNTAYN 84
14.11.1 COMPANY SNAPSHOT 84
14.11.2 PRODUCT PORTFOLIO 84
14.11.3 RECENT DEVELOPMENTS 84
14.12 KAYENTIS 85
14.12.1 COMPANY SNAPSHOT 85
14.12.2 PRODUCT PORTFOLIO 85
14.12.3 RECENT DEVELOPMENT 85
14.13 RAYLYTIC GMBH 86
14.13.1 COMPANY SNAPSHOT 86
14.13.2 PRODUCT PORTFOLIO 86
14.13.3 RECENT DEVELOPMENTS 86
14.14 TRANSPERFECT LIFE SCIENCES LIFE SCIENCES 87
14.14.1 COMPANY SNAPSHOT 87
14.14.2 PRODUCT PORTFOLIO 87
14.14.3 RECENT DEVELOPMENT 87
14.15 VITALOGRAPH 88
14.15.1 COMPANY SNAPSHOT 88
14.15.2 PRODUCT PORTFOLIO 88
14.15.3 RECENT DEVELOPMENTS 88
14.16 YPRIME LLC. 89
14.16.1 COMPANY SNAPSHOT 89
14.16.2 PRODUCT PORTFOLIO 89
14.16.3 RECENT DEVELOPMENTS 89
15 QUESTIONNAIRE 90
16 RELATED REPORTS 93